δ Opioid Receptor Inverse Agonists and their In Vivo Pharmacological Effects

Curr Top Med Chem. 2020;20(31):2889-2902. doi: 10.2174/1568026620666200402115654.

Abstract

The discovery of δ opioid receptor inverse agonist activity induced by ICI-174,864, which was previously reported as an δ opioid receptor antagonist, opened the door for the investigation of inverse agonism/constitutive activity of the receptors. Various peptidic or non-peptidic δ opioid receptor inverse agonists have since been developed. Compared with the reports dealing with in vitro inverse agonist activities of novel compounds or known compounds as antagonists, there have been almost no publications describing the in vivo pharmacological effects induced by a δ opioid receptor inverse agonist. After the observation of anorectic effects with the δ opioid receptor antagonism was discussed in the early 2000s, the short-term memory improving effects and antitussive effects have been very recently reported as possible pharmacological effects induced by a δ opioid receptor inverse agonist. In this review, we will survey the developed δ opioid receptor inverse agonists and summarize the possible in vivo pharmacological effects by δ opioid receptor inverse agonists. Moreover, we will discuss important issues involved in the investigation of the in vivo pharmacological effects produced by a δ opioid receptor inverse agonist.

Keywords: Anorectic effect; Antitussive effect; Constitutive activity; Inverse agonist; Neutral antagonist; Short-term memory improving effect; δ Opioid receptor.

Publication types

  • Review

MeSH terms

  • Analgesics, Opioid / chemistry
  • Analgesics, Opioid / pharmacology*
  • Enkephalin, Leucine / analogs & derivatives*
  • Enkephalin, Leucine / chemistry
  • Enkephalin, Leucine / pharmacology
  • Humans
  • Receptors, Opioid, delta / agonists*

Substances

  • Analgesics, Opioid
  • Receptors, Opioid, delta
  • Enkephalin, Leucine
  • N,N-diallyl-tyrosyl-alpha-aminoisobutyric acid-phenylalanyl-leucine